Advances in Treatment of Transfusion-dependent Lower-risk Myelodysplastic Syndromes
At present, the patients with transfusion-dependent lower-risk myelodysplastic syndromes (MDS) have limited treatment options when erythropoiesis-stimulating agent is ineffective or relapsed. With more understanding of the pathological and molecular genetics characteristics of MDS, the development o...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
FENG Yue [verfasserIn] LUO Xingchun [verfasserIn] ZHU Yu [verfasserIn] LIU Bei [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Chinesisch |
| Erschienen: |
2021 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Zhongliu Fangzhi Yanjiu - Magazine House of Cancer Research on Prevention and Treatment, 2019, 48(2021), 4, Seite 409-413 |
|---|---|
| Übergeordnetes Werk: |
volume:48 ; year:2021 ; number:4 ; pages:409-413 |
| Links: |
Link aufrufen |
|---|
| DOI / URN: |
10.3971/j.issn.1000-8578.2021.20.1020 |
|---|
| Katalog-ID: |
DOAJ068286015 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ068286015 | ||
| 003 | DE-627 | ||
| 005 | 20230309074427.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230228s2021 xx |||||o 00| ||chi c | ||
| 024 | 7 | |a 10.3971/j.issn.1000-8578.2021.20.1020 |2 doi | |
| 035 | |a (DE-627)DOAJ068286015 | ||
| 035 | |a (DE-599)DOAJ23d0b7fdac3d42818f485a7f64e49d0c | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 050 | 0 | |a RC254-282 | |
| 100 | 0 | |a FENG Yue |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Advances in Treatment of Transfusion-dependent Lower-risk Myelodysplastic Syndromes |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a At present, the patients with transfusion-dependent lower-risk myelodysplastic syndromes (MDS) have limited treatment options when erythropoiesis-stimulating agent is ineffective or relapsed. With more understanding of the pathological and molecular genetics characteristics of MDS, the development of precise medical treatment of MDS has been promoted. Small-molecule inhibitors, such as transforming growth factor β inhibiter, telomerase inhibiter and hypoxia-inducible factor prolyl hydroxylase inhibitor, provide novel therapeutic strategies for patients. This article reviews the treatment of transfusion-dependent lower-risk MDS patients and discusses the latest clinical research and development of novel targeted agents. | ||
| 650 | 4 | |a transfusion-dependency | |
| 650 | 4 | |a lower-risk myelodysplastic syndromes | |
| 650 | 4 | |a small-molecule inhibitors | |
| 653 | 0 | |a Neoplasms. Tumors. Oncology. Including cancer and carcinogens | |
| 700 | 0 | |a LUO Xingchun |e verfasserin |4 aut | |
| 700 | 0 | |a ZHU Yu |e verfasserin |4 aut | |
| 700 | 0 | |a LIU Bei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Zhongliu Fangzhi Yanjiu |d Magazine House of Cancer Research on Prevention and Treatment, 2019 |g 48(2021), 4, Seite 409-413 |w (DE-627)176063638X |x 10008578 |7 nnns |
| 773 | 1 | 8 | |g volume:48 |g year:2021 |g number:4 |g pages:409-413 |
| 856 | 4 | 0 | |u https://doi.org/10.3971/j.issn.1000-8578.2021.20.1020 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/23d0b7fdac3d42818f485a7f64e49d0c |z kostenfrei |
| 856 | 4 | 0 | |u http://html.rhhz.net/ZLFZYJ/html/8578.2021.20.1020.htm |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1000-8578 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1000-8578 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 48 |j 2021 |e 4 |h 409-413 | ||
| author_variant |
f y fy l x lx z y zy l b lb |
|---|---|
| matchkey_str |
article:10008578:2021----::dacsnramnotasuineednlwrikyl |
| hierarchy_sort_str |
2021 |
| callnumber-subject-code |
RC |
| publishDate |
2021 |
| allfields |
10.3971/j.issn.1000-8578.2021.20.1020 doi (DE-627)DOAJ068286015 (DE-599)DOAJ23d0b7fdac3d42818f485a7f64e49d0c DE-627 ger DE-627 rakwb chi RC254-282 FENG Yue verfasserin aut Advances in Treatment of Transfusion-dependent Lower-risk Myelodysplastic Syndromes 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier At present, the patients with transfusion-dependent lower-risk myelodysplastic syndromes (MDS) have limited treatment options when erythropoiesis-stimulating agent is ineffective or relapsed. With more understanding of the pathological and molecular genetics characteristics of MDS, the development of precise medical treatment of MDS has been promoted. Small-molecule inhibitors, such as transforming growth factor β inhibiter, telomerase inhibiter and hypoxia-inducible factor prolyl hydroxylase inhibitor, provide novel therapeutic strategies for patients. This article reviews the treatment of transfusion-dependent lower-risk MDS patients and discusses the latest clinical research and development of novel targeted agents. transfusion-dependency lower-risk myelodysplastic syndromes small-molecule inhibitors Neoplasms. Tumors. Oncology. Including cancer and carcinogens LUO Xingchun verfasserin aut ZHU Yu verfasserin aut LIU Bei verfasserin aut In Zhongliu Fangzhi Yanjiu Magazine House of Cancer Research on Prevention and Treatment, 2019 48(2021), 4, Seite 409-413 (DE-627)176063638X 10008578 nnns volume:48 year:2021 number:4 pages:409-413 https://doi.org/10.3971/j.issn.1000-8578.2021.20.1020 kostenfrei https://doaj.org/article/23d0b7fdac3d42818f485a7f64e49d0c kostenfrei http://html.rhhz.net/ZLFZYJ/html/8578.2021.20.1020.htm kostenfrei https://doaj.org/toc/1000-8578 Journal toc kostenfrei https://doaj.org/toc/1000-8578 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 48 2021 4 409-413 |
| spelling |
10.3971/j.issn.1000-8578.2021.20.1020 doi (DE-627)DOAJ068286015 (DE-599)DOAJ23d0b7fdac3d42818f485a7f64e49d0c DE-627 ger DE-627 rakwb chi RC254-282 FENG Yue verfasserin aut Advances in Treatment of Transfusion-dependent Lower-risk Myelodysplastic Syndromes 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier At present, the patients with transfusion-dependent lower-risk myelodysplastic syndromes (MDS) have limited treatment options when erythropoiesis-stimulating agent is ineffective or relapsed. With more understanding of the pathological and molecular genetics characteristics of MDS, the development of precise medical treatment of MDS has been promoted. Small-molecule inhibitors, such as transforming growth factor β inhibiter, telomerase inhibiter and hypoxia-inducible factor prolyl hydroxylase inhibitor, provide novel therapeutic strategies for patients. This article reviews the treatment of transfusion-dependent lower-risk MDS patients and discusses the latest clinical research and development of novel targeted agents. transfusion-dependency lower-risk myelodysplastic syndromes small-molecule inhibitors Neoplasms. Tumors. Oncology. Including cancer and carcinogens LUO Xingchun verfasserin aut ZHU Yu verfasserin aut LIU Bei verfasserin aut In Zhongliu Fangzhi Yanjiu Magazine House of Cancer Research on Prevention and Treatment, 2019 48(2021), 4, Seite 409-413 (DE-627)176063638X 10008578 nnns volume:48 year:2021 number:4 pages:409-413 https://doi.org/10.3971/j.issn.1000-8578.2021.20.1020 kostenfrei https://doaj.org/article/23d0b7fdac3d42818f485a7f64e49d0c kostenfrei http://html.rhhz.net/ZLFZYJ/html/8578.2021.20.1020.htm kostenfrei https://doaj.org/toc/1000-8578 Journal toc kostenfrei https://doaj.org/toc/1000-8578 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 48 2021 4 409-413 |
| allfields_unstemmed |
10.3971/j.issn.1000-8578.2021.20.1020 doi (DE-627)DOAJ068286015 (DE-599)DOAJ23d0b7fdac3d42818f485a7f64e49d0c DE-627 ger DE-627 rakwb chi RC254-282 FENG Yue verfasserin aut Advances in Treatment of Transfusion-dependent Lower-risk Myelodysplastic Syndromes 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier At present, the patients with transfusion-dependent lower-risk myelodysplastic syndromes (MDS) have limited treatment options when erythropoiesis-stimulating agent is ineffective or relapsed. With more understanding of the pathological and molecular genetics characteristics of MDS, the development of precise medical treatment of MDS has been promoted. Small-molecule inhibitors, such as transforming growth factor β inhibiter, telomerase inhibiter and hypoxia-inducible factor prolyl hydroxylase inhibitor, provide novel therapeutic strategies for patients. This article reviews the treatment of transfusion-dependent lower-risk MDS patients and discusses the latest clinical research and development of novel targeted agents. transfusion-dependency lower-risk myelodysplastic syndromes small-molecule inhibitors Neoplasms. Tumors. Oncology. Including cancer and carcinogens LUO Xingchun verfasserin aut ZHU Yu verfasserin aut LIU Bei verfasserin aut In Zhongliu Fangzhi Yanjiu Magazine House of Cancer Research on Prevention and Treatment, 2019 48(2021), 4, Seite 409-413 (DE-627)176063638X 10008578 nnns volume:48 year:2021 number:4 pages:409-413 https://doi.org/10.3971/j.issn.1000-8578.2021.20.1020 kostenfrei https://doaj.org/article/23d0b7fdac3d42818f485a7f64e49d0c kostenfrei http://html.rhhz.net/ZLFZYJ/html/8578.2021.20.1020.htm kostenfrei https://doaj.org/toc/1000-8578 Journal toc kostenfrei https://doaj.org/toc/1000-8578 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 48 2021 4 409-413 |
| allfieldsGer |
10.3971/j.issn.1000-8578.2021.20.1020 doi (DE-627)DOAJ068286015 (DE-599)DOAJ23d0b7fdac3d42818f485a7f64e49d0c DE-627 ger DE-627 rakwb chi RC254-282 FENG Yue verfasserin aut Advances in Treatment of Transfusion-dependent Lower-risk Myelodysplastic Syndromes 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier At present, the patients with transfusion-dependent lower-risk myelodysplastic syndromes (MDS) have limited treatment options when erythropoiesis-stimulating agent is ineffective or relapsed. With more understanding of the pathological and molecular genetics characteristics of MDS, the development of precise medical treatment of MDS has been promoted. Small-molecule inhibitors, such as transforming growth factor β inhibiter, telomerase inhibiter and hypoxia-inducible factor prolyl hydroxylase inhibitor, provide novel therapeutic strategies for patients. This article reviews the treatment of transfusion-dependent lower-risk MDS patients and discusses the latest clinical research and development of novel targeted agents. transfusion-dependency lower-risk myelodysplastic syndromes small-molecule inhibitors Neoplasms. Tumors. Oncology. Including cancer and carcinogens LUO Xingchun verfasserin aut ZHU Yu verfasserin aut LIU Bei verfasserin aut In Zhongliu Fangzhi Yanjiu Magazine House of Cancer Research on Prevention and Treatment, 2019 48(2021), 4, Seite 409-413 (DE-627)176063638X 10008578 nnns volume:48 year:2021 number:4 pages:409-413 https://doi.org/10.3971/j.issn.1000-8578.2021.20.1020 kostenfrei https://doaj.org/article/23d0b7fdac3d42818f485a7f64e49d0c kostenfrei http://html.rhhz.net/ZLFZYJ/html/8578.2021.20.1020.htm kostenfrei https://doaj.org/toc/1000-8578 Journal toc kostenfrei https://doaj.org/toc/1000-8578 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 48 2021 4 409-413 |
| allfieldsSound |
10.3971/j.issn.1000-8578.2021.20.1020 doi (DE-627)DOAJ068286015 (DE-599)DOAJ23d0b7fdac3d42818f485a7f64e49d0c DE-627 ger DE-627 rakwb chi RC254-282 FENG Yue verfasserin aut Advances in Treatment of Transfusion-dependent Lower-risk Myelodysplastic Syndromes 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier At present, the patients with transfusion-dependent lower-risk myelodysplastic syndromes (MDS) have limited treatment options when erythropoiesis-stimulating agent is ineffective or relapsed. With more understanding of the pathological and molecular genetics characteristics of MDS, the development of precise medical treatment of MDS has been promoted. Small-molecule inhibitors, such as transforming growth factor β inhibiter, telomerase inhibiter and hypoxia-inducible factor prolyl hydroxylase inhibitor, provide novel therapeutic strategies for patients. This article reviews the treatment of transfusion-dependent lower-risk MDS patients and discusses the latest clinical research and development of novel targeted agents. transfusion-dependency lower-risk myelodysplastic syndromes small-molecule inhibitors Neoplasms. Tumors. Oncology. Including cancer and carcinogens LUO Xingchun verfasserin aut ZHU Yu verfasserin aut LIU Bei verfasserin aut In Zhongliu Fangzhi Yanjiu Magazine House of Cancer Research on Prevention and Treatment, 2019 48(2021), 4, Seite 409-413 (DE-627)176063638X 10008578 nnns volume:48 year:2021 number:4 pages:409-413 https://doi.org/10.3971/j.issn.1000-8578.2021.20.1020 kostenfrei https://doaj.org/article/23d0b7fdac3d42818f485a7f64e49d0c kostenfrei http://html.rhhz.net/ZLFZYJ/html/8578.2021.20.1020.htm kostenfrei https://doaj.org/toc/1000-8578 Journal toc kostenfrei https://doaj.org/toc/1000-8578 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 48 2021 4 409-413 |
| language |
Chinese |
| source |
In Zhongliu Fangzhi Yanjiu 48(2021), 4, Seite 409-413 volume:48 year:2021 number:4 pages:409-413 |
| sourceStr |
In Zhongliu Fangzhi Yanjiu 48(2021), 4, Seite 409-413 volume:48 year:2021 number:4 pages:409-413 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
transfusion-dependency lower-risk myelodysplastic syndromes small-molecule inhibitors Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| isfreeaccess_bool |
true |
| container_title |
Zhongliu Fangzhi Yanjiu |
| authorswithroles_txt_mv |
FENG Yue @@aut@@ LUO Xingchun @@aut@@ ZHU Yu @@aut@@ LIU Bei @@aut@@ |
| publishDateDaySort_date |
2021-01-01T00:00:00Z |
| hierarchy_top_id |
176063638X |
| id |
DOAJ068286015 |
| language_de |
chinesisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ068286015</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309074427.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2021 xx |||||o 00| ||chi c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3971/j.issn.1000-8578.2021.20.1020</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ068286015</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ23d0b7fdac3d42818f485a7f64e49d0c</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">chi</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">FENG Yue</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Advances in Treatment of Transfusion-dependent Lower-risk Myelodysplastic Syndromes</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">At present, the patients with transfusion-dependent lower-risk myelodysplastic syndromes (MDS) have limited treatment options when erythropoiesis-stimulating agent is ineffective or relapsed. With more understanding of the pathological and molecular genetics characteristics of MDS, the development of precise medical treatment of MDS has been promoted. Small-molecule inhibitors, such as transforming growth factor β inhibiter, telomerase inhibiter and hypoxia-inducible factor prolyl hydroxylase inhibitor, provide novel therapeutic strategies for patients. This article reviews the treatment of transfusion-dependent lower-risk MDS patients and discusses the latest clinical research and development of novel targeted agents.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">transfusion-dependency</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">lower-risk myelodysplastic syndromes</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">small-molecule inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">LUO Xingchun</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">ZHU Yu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">LIU Bei</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Zhongliu Fangzhi Yanjiu</subfield><subfield code="d">Magazine House of Cancer Research on Prevention and Treatment, 2019</subfield><subfield code="g">48(2021), 4, Seite 409-413</subfield><subfield code="w">(DE-627)176063638X</subfield><subfield code="x">10008578</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:48</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:409-413</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3971/j.issn.1000-8578.2021.20.1020</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/23d0b7fdac3d42818f485a7f64e49d0c</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://html.rhhz.net/ZLFZYJ/html/8578.2021.20.1020.htm</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1000-8578</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1000-8578</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">48</subfield><subfield code="j">2021</subfield><subfield code="e">4</subfield><subfield code="h">409-413</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
FENG Yue |
| spellingShingle |
FENG Yue misc RC254-282 misc transfusion-dependency misc lower-risk myelodysplastic syndromes misc small-molecule inhibitors misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens Advances in Treatment of Transfusion-dependent Lower-risk Myelodysplastic Syndromes |
| authorStr |
FENG Yue |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)176063638X |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
RC254-282 |
| illustrated |
Not Illustrated |
| issn |
10008578 |
| topic_title |
RC254-282 Advances in Treatment of Transfusion-dependent Lower-risk Myelodysplastic Syndromes transfusion-dependency lower-risk myelodysplastic syndromes small-molecule inhibitors |
| topic |
misc RC254-282 misc transfusion-dependency misc lower-risk myelodysplastic syndromes misc small-molecule inhibitors misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| topic_unstemmed |
misc RC254-282 misc transfusion-dependency misc lower-risk myelodysplastic syndromes misc small-molecule inhibitors misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| topic_browse |
misc RC254-282 misc transfusion-dependency misc lower-risk myelodysplastic syndromes misc small-molecule inhibitors misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Zhongliu Fangzhi Yanjiu |
| hierarchy_parent_id |
176063638X |
| hierarchy_top_title |
Zhongliu Fangzhi Yanjiu |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)176063638X |
| title |
Advances in Treatment of Transfusion-dependent Lower-risk Myelodysplastic Syndromes |
| ctrlnum |
(DE-627)DOAJ068286015 (DE-599)DOAJ23d0b7fdac3d42818f485a7f64e49d0c |
| title_full |
Advances in Treatment of Transfusion-dependent Lower-risk Myelodysplastic Syndromes |
| author_sort |
FENG Yue |
| journal |
Zhongliu Fangzhi Yanjiu |
| journalStr |
Zhongliu Fangzhi Yanjiu |
| callnumber-first-code |
R |
| lang_code |
chi |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2021 |
| contenttype_str_mv |
txt |
| container_start_page |
409 |
| author_browse |
FENG Yue LUO Xingchun ZHU Yu LIU Bei |
| container_volume |
48 |
| class |
RC254-282 |
| format_se |
Elektronische Aufsätze |
| author-letter |
FENG Yue |
| doi_str_mv |
10.3971/j.issn.1000-8578.2021.20.1020 |
| author2-role |
verfasserin |
| title_sort |
advances in treatment of transfusion-dependent lower-risk myelodysplastic syndromes |
| callnumber |
RC254-282 |
| title_auth |
Advances in Treatment of Transfusion-dependent Lower-risk Myelodysplastic Syndromes |
| abstract |
At present, the patients with transfusion-dependent lower-risk myelodysplastic syndromes (MDS) have limited treatment options when erythropoiesis-stimulating agent is ineffective or relapsed. With more understanding of the pathological and molecular genetics characteristics of MDS, the development of precise medical treatment of MDS has been promoted. Small-molecule inhibitors, such as transforming growth factor β inhibiter, telomerase inhibiter and hypoxia-inducible factor prolyl hydroxylase inhibitor, provide novel therapeutic strategies for patients. This article reviews the treatment of transfusion-dependent lower-risk MDS patients and discusses the latest clinical research and development of novel targeted agents. |
| abstractGer |
At present, the patients with transfusion-dependent lower-risk myelodysplastic syndromes (MDS) have limited treatment options when erythropoiesis-stimulating agent is ineffective or relapsed. With more understanding of the pathological and molecular genetics characteristics of MDS, the development of precise medical treatment of MDS has been promoted. Small-molecule inhibitors, such as transforming growth factor β inhibiter, telomerase inhibiter and hypoxia-inducible factor prolyl hydroxylase inhibitor, provide novel therapeutic strategies for patients. This article reviews the treatment of transfusion-dependent lower-risk MDS patients and discusses the latest clinical research and development of novel targeted agents. |
| abstract_unstemmed |
At present, the patients with transfusion-dependent lower-risk myelodysplastic syndromes (MDS) have limited treatment options when erythropoiesis-stimulating agent is ineffective or relapsed. With more understanding of the pathological and molecular genetics characteristics of MDS, the development of precise medical treatment of MDS has been promoted. Small-molecule inhibitors, such as transforming growth factor β inhibiter, telomerase inhibiter and hypoxia-inducible factor prolyl hydroxylase inhibitor, provide novel therapeutic strategies for patients. This article reviews the treatment of transfusion-dependent lower-risk MDS patients and discusses the latest clinical research and development of novel targeted agents. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ |
| container_issue |
4 |
| title_short |
Advances in Treatment of Transfusion-dependent Lower-risk Myelodysplastic Syndromes |
| url |
https://doi.org/10.3971/j.issn.1000-8578.2021.20.1020 https://doaj.org/article/23d0b7fdac3d42818f485a7f64e49d0c http://html.rhhz.net/ZLFZYJ/html/8578.2021.20.1020.htm https://doaj.org/toc/1000-8578 |
| remote_bool |
true |
| author2 |
LUO Xingchun ZHU Yu LIU Bei |
| author2Str |
LUO Xingchun ZHU Yu LIU Bei |
| ppnlink |
176063638X |
| callnumber-subject |
RC - Internal Medicine |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.3971/j.issn.1000-8578.2021.20.1020 |
| callnumber-a |
RC254-282 |
| up_date |
2024-07-03T16:54:24.194Z |
| _version_ |
1803577630858936320 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ068286015</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309074427.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2021 xx |||||o 00| ||chi c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3971/j.issn.1000-8578.2021.20.1020</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ068286015</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ23d0b7fdac3d42818f485a7f64e49d0c</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">chi</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">FENG Yue</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Advances in Treatment of Transfusion-dependent Lower-risk Myelodysplastic Syndromes</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">At present, the patients with transfusion-dependent lower-risk myelodysplastic syndromes (MDS) have limited treatment options when erythropoiesis-stimulating agent is ineffective or relapsed. With more understanding of the pathological and molecular genetics characteristics of MDS, the development of precise medical treatment of MDS has been promoted. Small-molecule inhibitors, such as transforming growth factor β inhibiter, telomerase inhibiter and hypoxia-inducible factor prolyl hydroxylase inhibitor, provide novel therapeutic strategies for patients. This article reviews the treatment of transfusion-dependent lower-risk MDS patients and discusses the latest clinical research and development of novel targeted agents.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">transfusion-dependency</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">lower-risk myelodysplastic syndromes</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">small-molecule inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">LUO Xingchun</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">ZHU Yu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">LIU Bei</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Zhongliu Fangzhi Yanjiu</subfield><subfield code="d">Magazine House of Cancer Research on Prevention and Treatment, 2019</subfield><subfield code="g">48(2021), 4, Seite 409-413</subfield><subfield code="w">(DE-627)176063638X</subfield><subfield code="x">10008578</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:48</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:409-413</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3971/j.issn.1000-8578.2021.20.1020</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/23d0b7fdac3d42818f485a7f64e49d0c</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://html.rhhz.net/ZLFZYJ/html/8578.2021.20.1020.htm</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1000-8578</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1000-8578</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">48</subfield><subfield code="j">2021</subfield><subfield code="e">4</subfield><subfield code="h">409-413</subfield></datafield></record></collection>
|
| score |
7.4013834 |